From a previous post concerning ASCO
>>The plenary session will also feature new data from 2 phase 3 clinical trials, one with bevacizumab (Avastin) in ovarian cancer (abstract LBA1), and the other with the novel immunomodulatory compound ipilimumab in metastatic melanoma (abstract 4).
There was excitement about the potential for ipilimumab in the treatment of melanoma when data from several phase 2 clinical trials were presented at ASCO 2008, as reported at the time by Medscape Oncology. Since then, this drug has shown activity in prostate cancer that has been described as "dramatic," but the report was based on only 2 patients.<<<
What or who is presenting an abstract on ipilimumab? When I searched it, only GETA appeared but nothing else.
